ARA-290
ARA-290 (cibinetide) is a lab-made chain of 11 amino acids modelled on the helix-B region of erythropoietin, a hormone known for driving red blood cell production. It is studied for nerve and tissue protection in animal models and small human trials.
At a glance
- Peptide
- Not yet audited here; the reference library calls it emerging
- 4 mg per Peptide Protocol Wiki. See the source
How much to draw
Full calculator →Opened on 4 mg, the figure Peptide Protocol Wiki reports for ARA-290. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for ARA-290 or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 4 mg | Once daily28 days | subcutaneous or intranasal or oral | Peptide Protocol Wiki |
- Once daily28 days
- subcutaneous or intranasal or oral
- Peptide Protocol Wiki
We have not published an audit on ARA-290. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
ARA-290 is designed to switch on a protective signal in stressed or injured tissue without raising red blood cell production the way erythropoietin does. In a rat nerve-injury model it reduced pain-like responses to touch and cold, and small human trials reported changes in corneal nerve fibre measures. Researchers link this to the innate repair receptor, a complex of the erythropoietin receptor and the beta-common receptor (CD131). The source cautions that receptor activity and animal results can fail to turn into meaningful benefit in people.
Reported side effects
Seen in studies: a 2012 double-blind pilot study of 22 patients, given 2 mg by vein three times weekly for 4 weeks, reported no safety concerns. A 12-week open-label pilot of daily 4 mg under the skin in diabetic macular edema is described as informing feasibility and safety monitoring. The source names no specific adverse events or rates.
Not ruled out: safety data are limited by small studies, short follow-up and investigational use. Questions about drug interactions, pregnancy, breastfeeding, blood clots (thrombosis), cancer and immune disease remain unanswered.
Who should avoid it
People who are pregnant or breastfeeding: the source says these questions remain unanswered because safety data are limited.
People with a history of blood clots or cancer: approved erythropoiesis-stimulating drugs carry major warnings on thrombosis, cardiovascular events and tumour progression. ARA-290 was engineered to avoid that activity, but the source says this does not prove it safe for all users.
People with immune disease: unanswered, because the safety data come from small, short studies.
People on other medicines: drug interactions remain an open question for the same reason.
What gets monitored
The page mentions the following assessments used in clinical trials that could inform monitoring: corneal nerve fiber area and corneal nerve fiber density (via corneal confocal microscopy), intraepidermal nerve fiber markers, Small Fiber Neuropathy Screening List scores, Brief Pain Inventory, PainDetect scores, fatigue scales, quality-of-life measures, HbA1c, and lipid measures. These are described as study endpoints, not as a formal monitoring protocol. (reported by Peptide Dosages)
Sources
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
5-Amino-1MQ (5-amino-1-methylquinolinium) is a small lab-made molecule, not a true peptide, though it is often sold alongside research peptides. It is studied for shrinking fat cells and raising NAD+ levels, and all evidence so far comes from cell and rodent studies, with no published human trial.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
Cerluten is an oral peptide bioregulator referenced for nervous system support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.
CJC-1295 with DAC is a lab-made 30-amino-acid copy of growth hormone-releasing hormone, altered so it attaches to albumin, a protein in the blood. It was studied in early human trials for its effect on growth hormone and IGF-1 levels.
This is a combination research blend sold as one vial: CJC-1295 without DAC, a copy of growth hormone-releasing hormone, plus Ipamorelin, a short peptide that acts on the ghrelin receptor. It is studied as a GHRH and GHRP pairing in growth-hormone research.
Endoluten is a peptide bioregulator taken by mouth, listed in the reference library as pineal support. Its proposed action, tissue-specific peptide bioregulation, is described as theoretical.